https://www.selleckchem.com/pr....oducts/Acetylcholine
21, 95% CI -0.98 to 1.4), reduction in BNP/NT-proBNP (β coefficient -12.16, 95% CI -30.68 to 6.37), increase in tricuspid annular plane systolic excursion (β coefficient 0.074, 95% CI 0.010-0.139), or decrease in pulmonary artery systolic pressure (0.996, 95% CI 0.991-1.011) in CpcPH with therapy. There was higher mortality in CpcPH compared to PAH on treatment (24% vs 4%, P = .003). There were no improvements in symptoms, exercise capacity, or echocardiographic parameters with PAH-targeted therapy in CpcPH. Further studi
Beğen
Yorum Yap
Paylaş
